Hormonal changes during GnRH analogue therapy in children with central precocious puberty

Journal of Pediatric Endocrinology and Metabolism

Volumn 13, Issue SUPPL. 1, 2000, Pages 739-746

  Muller, J ^a   Juul, A ^a   Andersson, A M ^a   Sehested, A ^a   Skakkebaek, N E ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Free IGF I; GnRH analogue; IGF I; IGFBP 3; Inhibin A; Inhibin B; Precocious puberty; Prostate specific antigen

Indexed keywords

ANDROGEN; ESTRADIOL; FOLLITROPIN; GONADORELIN DERIVATIVE; GROWTH HORMONE; INHIBIN A; INHIBIN B; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C; TESTOSTERONE;

BODY HEIGHT; CONFERENCE PAPER; DRUG SAFETY; GROWTH HORMONE RELEASE; HORMONE INHIBITION; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; PRECOCIOUS PUBERTY;

EID: 0033851088     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.2000.13.s1.739     Document Type: Conference Paper

References (33)

1. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone
2. Effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty
3. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: Effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate)
4. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: Long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty
5. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious puberty and early puberty
6. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females
7. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay
8. Development of a specific and sensitive two-site enzyme-linked immunoadsorbent assay for measurement of inhibin-A in serum
9. Measurement of dimeric inhibin B throughout the human menstrual cycle
10. Serum inhibin A and inhibin B in healthy prepubertal, pubertal and adolescent girls and adult women: Relation to age, stage of puberty, menstrual cycle, FSH, LH and estradiol levels
11. Different roles of prepubertal and postpubertal germ cells and Sertoli cells in the regulation of inhibin B levels
12. Changes in dimeric inhibin A and B during normal early puberty in boys and girls
13. Regulation of biologically active dimeric inhibin A and B from infancy to adulthood in the male
14. Inhibin-B: A likely candidate for the physiologically important form of inhibin in man
15. Inhibin B as a serum marker of spermatogenesis: Correlation to differences in sperm concentration and follicle-stimulating hormone levels
16. Serum inhibin B in healthy pubertal and adolescent boys: Relation to age, stage of puberty, and follicle-stimulating hormone, luteinizing hormone, testosterone and estradiol levels
17. Prostate specific antigen in boys with precocious puberty before and during gonadal suppression by GnRH agonist treatment
18. Serum prostate specific antigen, sex hormone binding globulin and free androgen index as markers of pubertal development in boys
19. Serum prostate-specific antigen measured in children from birth to age 18 years
20. Serum levels of prostate-specific antigen in normal boys throughout puberty
21. The effect of androgens on the pulsatile release and the twenty-four-hour mean concentration of growth hormone in peripubertal males
22. Alteration in the nocturnal pulsatile release of growth hormone during the induction of puberty using low dose pulsatile LHRH: A case report
23. Serum insulin-like growth factor-1 in 1030 healthy children, adolescents and adults; relation to age, sex, stage of puberty, testicular size and body mass index
24. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: The relation to IGF-I, IGF-II, IGFBP-I, IGFBP-2, age, sex, body mass index, and pubertal maturation
25. Increase in free insulin-like growth factor-I levels in precocious and normal puberty
26. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency
27. Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal and precocious puberty
28. Suppression of the pituitary-gonadal axis in children with central precocious puberty: Effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion
29. Low growth hormone levels are related to increased body mass index and do not reflect impaired growth in luteinizing hormone-releasing hormone agonist-treated children with precocious puberty
30. The effect of long-acting analog of luteinizing hormone-releasing hormone on growth hormone secretory dynamics in children with precocious puberty
31. Serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 levels in children with precocious puberty treated with gonadotropin releasing hormone analog without or in combination with cyproterone acetate
32. Insulin-like growth factor-I and IGF binding protein-3 remain high after GnRH analogue therapy in girls with central precocious puberty
33. Irreversible increase of serum IGF-I and IGFBP-3 levels in GnRH-dependent precocious puberty of different etiologies: Implications for the onset of puberty